Study guide

20.1 Site Qualification and Investigator Capacity

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

20.1 Site Qualification and Investigator Capacity

Key Takeaways Explain This Topic AI

Site suitability includes qualifications, time, staff, facilities and appropriate participants.

A feasibility survey needs supporting evidence rather than optimism alone.

ICH does not set a universal maximum number of trials per investigator.

Last updated: October 2026

Site Qualification and Investigator Capacity

Note

Selecting qualified clinical investigative sites is a major factor in determining whether a clinical trial finishes on schedule, stays within budget, and generates robust, inspectable scientific data. Under ICH E6(R3), the sponsor must ensure that each designated investigator is qualified by education, training, and experience, and has adequate resources—including time, personnel, facilities, and eligible participants—to conduct the study to completion in full compliance with Good Clinical Practice (GCP).

In clinical research, the Clinical Research Associate (CRA) serves as the sponsor's investigative eyes and ears during the site selection process. While commercial sponsor business development teams or CRO feasibility departments initiate site identification through electronic surveys, the CRA validates these representations in the physical clinic.

A misjudged site selection—such as selecting a renowned academic investigator who lacks time to oversee study staff, or a private clinic with an inadequate patient referral network—leads directly to delayed study milestones, poor data quality, protocol non-compliance, and costly rescue site activations.

Feasibility Questionnaires vs. Pre-Study Visits (PSV/SQV)

Site evaluation follows a progressive funnel that transitions from broad statistical surveying to granular, in-person operational verification.

The Site Feasibility Questionnaire (SFQ)

Before any proprietary protocol information is shared, the investigative site and sponsor execute a mutual Confidential Disclosure Agreement (CDA) . Once protected, the site receives a protocol synopsis and a structured Site Feasibility Questionnaire (SFQ) . The SFQ collects self-reported institutional metrics, including:

Estimated monthly patient volume matching broad inclusion/exclusion criteria.

Active competing clinical trials in the same indication.

Standard-of-care diagnostics and hospital department capabilities.

Institutional Review Board (IRB) or Independent Ethics Committee (IEC) review timelines and reliance policies.

Site staff credentials and dedicated research staffing levels.

The Pre-Study Visit (PSV) / Site Qualification Visit (SQV)

While the SFQ provides a preliminary quantitative baseline, self-reported metrics are notoriously susceptible to optimistic bias. Recruitment estimates may be optimistic and need an evidence-based rationale. The Pre-Study Visit (PSV) —also termed the Site Qualification Visit (SQV) —represents the formal audit step where the CRA verifies the physical reality of the site's written responses.

Assessment Parameter Feasibility Questionnaire (SFQ) Pre-Study Qualification Visit (PSV/SQV)

Format Written or electronic survey completed by coordinator or investigator. Multi-hour on-site (or comprehensive qualified remote) interactive inspection.

Focus Self-reported institutional capacities and theoretical patient counts. Physical verification of facilities, equipment, staff availability, and clinical charts.

Investigator Role Passive; frequently reviews and signs questionnaire completed by a CRC. Active; formal face-to-face interview evaluating medical expertise and personal commitment.

Verification Depth Low; numbers are unverified claims. High; CRA cross-references medical records, temperature logs, and competing trial lists.

Outcome Screening triage to determine which sites warrant an on-site visit. Formal CRA recommendation for site approval, conditional remediation, or rejection.

Critical Evaluation Domains During the PSV/SQV

During the PSV, the CRA executes a systematic evaluation of five core operational pillars required under ICH E6(R3):

A. Investigator Qualifications, Specialty & Verifiable Time

Under ICH E6(R3), the investigator must be qualified by education, training, and experience, and must have adequate time to properly supervise the trial. The CRA must evaluate:

Medical Specialty & Board Certification: The PI's therapeutic background must directly match the study indication (e.g., a board-certified medical oncologist for a Phase III solid-tumor trial, or an experienced neurologist for an Alzheimer's disease investigation).

GCP Fluency & Trial Experience: Prior clinical trial experience as a PI or Sub-investigator, familiarity with electronic data capture (EDC), and verifiable GCP training certificates (maintained under applicable training requirements).

The "Overextended PI" Syndrome: A prominent clinical researcher or department chair may attract numerous study awards but possess zero bandwidth for actual day-to-day supervision. The CRA must explicitly calculate the PI's current commitments: hospital inpatient rounds, surgical schedules, private clinic hours, academic teaching duties, and existing active research trials. If a PI manages 15 active clinical trials while maintaining a full surgical schedule, human subject oversight is severely jeopardized.

Scientific Engagement: Does the PI demonstrate genuine enthusiasm for the protocol's scientific objectives, or is the trial viewed merely as a secondary revenue stream?

B. Site Staff Resources & Workload Balancing

Trial execution depends heavily on the operational competence and stability of the site's research infrastructure:

Clinical Research Coordinator (CRC) Bandwidth: The lead study coordinator is the central administrative engine of the trial. The CRA must determine how many active studies each coordinator manages. Assess coordinator capacity from the actual workload, complexity, staffing and backup, without a universal study-count ceiling.

Dedicated Support Staff: Presence of dedicated research nurses, phlebotomists, certified unblinded study pharmacists, and clinical data entry personnel.

Staff Turnover & Retention: High coordinator turnover is an immediate operational hazard, causing lost institutional knowledge, missing documentation, and training gaps.

Back-Up Coverage: Documented availability of cross-trained backup coordinators and sub-investigators who can maintain study continuity during planned leaves or unexpected departures.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .